Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function

Gastroenterology

Volumn 149, Issue 1, 2015, Pages 190-200.e2

  Serti, Elisavet ^a,b   Chepa Lotrea, Xenia ^a,b   Kim, Yun Ju ^b   Keane, Meghan ^a,b   Fryzek, Nancy ^b   Liang, T Jake ^b   Ghany, Marc ^b   Rehermann, Barbara ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Immune Regulation; ISG; NS3 Inhibitor; NS5A Inhibitor

Indexed keywords

ASUNAPREVIR; CXCL11 CHEMOKINE; DACLATASVIR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; PEGINTERFERON; RIBAVIRIN; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ALPHA INTERFERON; ANTIVIRUS AGENT; CXCL10 PROTEIN, HUMAN; CXCL11 PROTEIN, HUMAN; CYTOKINE; VIRUS RNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MALE; NATURAL KILLER CELL; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOLOGY; METABOLISM; MIDDLE AGED; TIME; TREATMENT OUTCOME;

AGED; ANTIVIRAL AGENTS; CHEMOKINE CXCL10; CHEMOKINE CXCL11; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 84931378182     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.03.004     Document Type: Article

References (30)

1. B. Rehermann Pathogenesis of chronic viral hepatitis. Differential roles of T cells and NK cells Nat Med 19 2013 859 868
2. M. Sarasin-Filipowicz, E.J. Oakeley, and F.H. Duong Interferon signaling and treatment outcome in chronic hepatitis C Proc Natl Acad Sci U S A 105 2008 7034 7039
3. G. Askarieh, A. Alsio, and P. Pugnale Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C Virus RNA and overall viral response to therapy in chronic hepatitis C Hepatology 51 2010 1523 1530
4. D.G. Doherty, and C. O'Farrelly Innate and adaptive lymphoid cells in the human liver Immunol Rev 174 2000 5 20
5. T. Miyagi, T. Takehara, and K. Nishio Altered interferon-alpha-signaling in natural killer cells from patients with chronic hepatitis C virus infection J Hepatol 53 2010 424 430
6. B. Edlich, G. Ahlenstiel, and A. Zabaleta Azpiroz Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients Hepatology 55 2012 39 48
7. G. Ahlenstiel, R.H. Titerence, and C. Koh Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner Gastroenterology 138 2010 325 335
8. M.U. Mondelli, S. Varchetta, and B. Oliviero Natural killer cells in viral hepatitis: facts and controversies Eur J Clin Invest 40 2010 851 863
9. B. Oliviero, S. Varchetta, and E. Paudice Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections Gastroenterology 137 2009 1151 1160
10. T.J. Liang, and M.G. Ghany Current and future therapies for hepatitis C virus infection N Engl J Med 368 2013 1907 1917
11. T.J. Liang, and M.G. Ghany Therapy of hepatitis C-back to the future N Engl J Med 370 2014 2043 2047
12. H. Wedemeyer, X.S. He, and M. Nascimbeni Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection J Immunol 169 2002 3447 3458
13. B. Bengsch, B. Seigel, and M. Ruhl Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation PLoS Pathog 6 2010 e1000947
14. B. Martin, N. Hennecke, and V. Lohmann Restoration of HCV-specific CD8+ T cell function by interferon-free therapy J Hepatol 61 2014 1212 1219
15. B. Rehermann, and A. Bertoletti Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections Hepatology 61 2015 712 721
16. M.T. Dill, Z. Makowska, and G. Trincucci Pegylated IFN-alpha regulates hepatic gene expression through transient Jak/STAT activation J Clin Invest 124 2014 1568 1581
17. G. Ahlenstiel, B. Edlich, and L.J. Hogdal Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C Gastroenterology 141 2011 1231 1239
18. B. Oliviero, D. Mele, and E. Degasperi Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection J Hepatol 59 2013 38 44
19. M. Gao, R.E. Nettles, and M. Belema Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100
20. L. Moretta, C. Bottino, and D. Pende Human natural killer cells: their origin, receptors and function Eur J Immunol 32 2002 1205 1211
21. K.A. Stegmann, N.K. Bjorkstrom, and H. Veber Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection Gastroenterology 138 2010 1885 1897
22. T. Miyagi, S. Shimizu, and T. Tatsumi Differential alteration of CD56(bright) and CD56 (dim) natural killer cells in frequency, phenotype, and cytokine response in chronic hepatitis C virus infection J Gastroenterol 46 2011 1020 1030
23. E.G. Meissner, D. Wu, and A. Osinusi Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome J Clin Invest 124 2014 3352 3363
24. E.C. Shin, U. Seifert, and T. Kato Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection J Clin Invest 116 2006 3006 3014
25. S. Wieland, R. Thimme, and R.H. Purcell Genomic analysis of the host response to hepatitis B virus infection Proc Natl Acad Sci U S A 101 2004 6669 6674
26. E.B. Wilson, D.H. Yamada, and H. Elsaesser Blockade of chronic type I interferon signaling to control persistent LCMV infection Science 340 2013 202 207
27. J.R. Teijaro, C. Ng, and A.M. Lee Persistent LCMV infection is controlled by blockade of type I interferon signaling Science 340 2013 207 211
28. A. De Maria, M. Fogli, and S. Mazza Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients Eur J Immunol 37 2007 445 455
29. J. Nattermann, G. Feldmann, and G. Ahlenstiel Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C Gut 55 2006 869 877
30. O. Dessouki, Y. Kamiya, and H. Nagahama Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: reversion by anti-viral treatment Biochem Biophys Res Commun 393 2010 331 337